Company news

OPKO Health, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024

July 31, 2024

OPKO Health Announces $100 Million Share Repurchase Program

July 17, 2024

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments

July 16, 2024

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 30, 2024

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 6, 2024

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

May 2, 2024

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

February 26, 2024

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

February 21, 2024

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes

January 8, 2024

OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

January 3, 2024

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

January 2, 2024

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

November 27, 2023

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

November 5, 2023

New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

November 1, 2023

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

October 30, 2023

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

October 24, 2023

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

September 27, 2023

OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results

August 2, 2023

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

July 24, 2023

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

May 2, 2023

OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023

April 24, 2023

OPKO Health to Hold Virtual R&D Day on March 20, 2023

March 8, 2023

OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate

March 7, 2023

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

February 22, 2023

OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023

February 15, 2023

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings

February 8, 2023

OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results

November 7, 2022

OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022

October 31, 2022

OPKO Health Announces Leadership Changes for BioReference Laboratories

August 15, 2022

OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results

August 3, 2022

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

July 24, 2022

OPKO Health to Present at the 2022 Jefferies Healthcare Conference

June 1, 2022

OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results

May 8, 2022

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

May 8, 2022

OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

May 4, 2022

GeneDx Announces Discovery of 200 New and Expanded Genetic Conditions

March 15, 2022

Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease

February 28, 2022

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

February 23, 2022

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

February 16, 2022

Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

February 14, 2022

RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

February 2, 2022

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

January 20, 2022

Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

January 19, 2022

OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

December 22, 2021

OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

December 7, 2021

OPKO Health Announces the Passing of Director Dr. Richard Lerner

December 5, 2021

OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

November 28, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.